Cann Group (ASX:CAN) - Prezzo delle azioni, notizie e analisi

CAN Panoramica delle azioni

Cann Group Limited, insieme alle sue controllate, si occupa di allevamento, coltivazione, produzione e vendita di cannabis terapeutica in Australia e in Europa.

Informazioni sull'azienda

CAN analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Analisi del rischio

Gli utili sono diminuiti del 23.8% all'anno negli ultimi 5 anni

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Non ha una capitalizzazione di mercato significativa ( A$20M )

Gli azionisti sono stati diluiti nell'ultimo anno

Cann Group Limited Concorrenti

Althea Group Holdings

ASX:AGH

AU$24.4m

Rhinomed

ASX:RNO

AU$11.5m

Invion

ASX:IVX

AU$13.5m

Nyrada

ASX:NYR

AU$20.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cann Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.043
Massimo di 52 settimane	AU$0.19
Minimo di 52 settimane	AU$0.027
Beta	1.09
1Variazione di 1 mese	-38.57%
Variazione a 3 mesi	13.16%
Variazione di 1 anno	-62.61%
3Variazione a 3 anni	-84.91%
Variazione a 5 anni	-95.96%
Variazione dall'IPO	-93.33%

Notizie e aggiornamenti recenti

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Sep 24

Recent updates

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Sep 24

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

Rendimenti per gli azionisti

	CAN	AU Pharmaceuticals	AU Mercato
7D	7.5%	-2.3%	-1.1%
1Y	-62.6%	61.9%	16.1%

Ritorno vs Industria: CAN ha avuto una performance inferiore rispetto al Australian Pharmaceuticals che ha registrato un rendimento 61.9 % nell'ultimo anno.

Rendimento vs Mercato: CAN ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 16.1 % nell'ultimo anno.

Volatilità dei prezzi

Is CAN's price volatile compared to industry and market?
CAN volatility
CAN Average Weekly Movement	23.0%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.7%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.6%

Prezzo delle azioni stabile: Il prezzo delle azioni di CAN è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di CAN è aumentata da 16% a 23% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	n/a	Jenni Pilcher	www.canngrouplimited.com

Cann Group Limited, insieme alle sue controllate, si occupa di allevamento, coltivazione, produzione e vendita di cannabis terapeutica in Australia e in Europa. Inoltre, concede licenze per intraprendere ricerche e coltivare cannabis per scopi terapeutici e di ricerca. La società è stata fondata nel 2014 e ha sede a Port Melbourne, in Australia.

Cann Group Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cann Group con la sua capitalizzazione di mercato?
CAN statistiche fondamentali
Capitalizzazione di mercato	AU$20.16m
Guadagni(TTM)	-AU$51.24m
Ricavi(TTM)	AU$18.36m

1.1x

Rapporto P/S

-0.4x

Rapporto P/E

CAN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CAN Conto economico (TTM)
Ricavi	AU$18.36m
Costo del fatturato	AU$12.18m
Profitto lordo	AU$6.18m
Altre spese	AU$57.42m
Guadagni	-AU$51.24m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.11
Margine lordo	33.66%
Margine di profitto netto	-279.13%
Rapporto debito/patrimonio netto	516.6%

Come si è comportato CAN nel lungo periodo?

Vedi performance storica e confronto

CAN Panoramica delle azioni

Premi

Analisi del rischio

Cann Group Limited Concorrenti

ASX:AGH

AU$24.4m

ASX:RNO

AU$11.5m

ASX:IVX

AU$13.5m

ASX:NYR

AU$20.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Recent updates

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock